Acceptability & Impact of a Diabetes Management Smartphone App (mySugr) for Spanish-literate Adults With Type 2 Diabetes
NCT05975242 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32
Last updated 2024-12-05
Summary
The goal of this clinical trial is to compare those using a diabetes management smartphone application (mySugr) to those not using the application. This smartphone application is for Spanish-literate adults with poorly controlled, non-intensively treated type 2 diabetes (T2D).
The main question\[s\] that it aims to answer are:
* What is the impact of the use of mySugr (a smartphone-based application or app) with structured blood glucose monitoring on diabetes self-management among Hispanic/Latino adults with poorly controlled, non-intensively treated T2D?
* Will diabetes self-management be more effective for those using mySugr (the Active group) compared to those not using mySugr (the Control group) over a 12-week study period? Participants will be screened and enrolled if they are eligible; they will have the study explained to them in Spanish or English and have time to ask questions and then sign an informed consent form. Clinical measurements (including height, weight, and blood pressure) and hemoglobin A1c will be done. All subjects will be given a blood glucose meter, lancing device, and blood glucose strips for the meter, and they will also receive an electronic scale. Several questionnaires will be answered.
If a subject is randomly assigned to the Active group, they will download the mySugr PRO (professional) app in Spanish to their smartphone and be trained in its use. They will receive education focused on paired (before and 2 hours after a meal) blood glucose testing, which participants will conduct twice a day for 6 days and once a month for 3 months. Participants will continue structured blood glucose testing with the mySugr PRO app for 12 weeks, and they will have 3 virtual visits in Spanish with mySugr PRO coaches who will review the blood glucose records and advise the subjects.
Subjects in the Control group will not receive the mySugr PRO app or coaching. They will continue with their usual diabetes management.
All subjects will return after 12 weeks to return the scale and have a close-out visit with clinical measurements and questionnaires. Subjects will also receive a disturbance allowance for their time and participation.
Conditions
- Diabetes Mellitus, Type 2
Interventions
- BEHAVIORAL
-
Smartphone diabetes management application
The intervention is a smartphone diabetes management application that is combined with structured blood glucose testing.
Sponsors & Collaborators
-
Roche Pharma AG
collaborator INDUSTRY -
Sansum Diabetes Research Institute
lead OTHER
Principal Investigators
-
Ashley Thorsell, MD · Sansum Diabetes Research Institute
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-04-04
- Primary Completion
- 2024-04-01
- Completion
- 2024-04-01
Countries
- United States
Study Locations
More Related Trials
-
A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.
NCT00755287 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Type 2 Diabetes Pharmacotherapy Regimens
NCT05073692 ·Status: COMPLETED
-
Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin
NCT00135057 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes
NCT01127269 ·Status: COMPLETED ·Phase: PHASE4
-
Lantus Versus Levemir Treat-To-Target
NCT00405418 ·Status: COMPLETED ·Phase: PHASE4
-
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin
NCT02967211 ·Status: COMPLETED ·Phase: PHASE4
-
A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
NCT01794143 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes
NCT04484779 ·Status: COMPLETED ·Phase: NA
-
Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients
NCT02666430 ·Status: COMPLETED ·Phase: PHASE3
-
Insulin Glargine Benefits in Japanese Pts Outside of Japan (US or Brazil)
NCT00642915 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin Treatment
NCT02967237 ·Status: COMPLETED ·Phase: PHASE4
-
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists
NCT07325435 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control
NCT00283049 ·Status: TERMINATED ·Phase: PHASE4
-
Insulin Glargine in Type 2 Diabetic Patients
NCT00347100 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of LY2605541 Versus Insulin Glargine on Blood Sugar
NCT01654380 ·Status: COMPLETED ·Phase: PHASE1
-
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice
NCT05443334 ·Status: COMPLETED
-
Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin
NCT03760991 ·Status: COMPLETED ·Phase: PHASE4
-
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
NCT01204593 ·Status: COMPLETED ·Phase: PHASE4
-
20 Week Bridging Study in Type II DM
NCT00563225 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes
NCT00395746 ·Status: COMPLETED ·Phase: PHASE3
-
Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment
NCT00046462 ·Status: COMPLETED ·Phase: PHASE3
-
Lispro Mix 25 vs. Glargine in Type 2 Diabetics
NCT00551356 ·Status: COMPLETED ·Phase: PHASE3
-
Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study
NCT01121835 ·Status: COMPLETED ·Phase: PHASE4
-
Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus
NCT01226043 ·Status: COMPLETED ·Phase: PHASE4
-
A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes
NCT01880736 ·Status: COMPLETED ·Phase: PHASE3